{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:58:19Z","timestamp":1789912699395,"version":"4.0.1"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2017-0905_s_999_w2aab3b7c80b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Antinuclear antibodies (ANAs) are useful for the diagnosis of ANA-associated systemic rheumatic disease (AASRD). The objective of this study was the evaluation of an immunoassay that detects antibodies to a mixture of 17 antigens as an alternative to indirect immunofluorescence (IIF).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0905_s_998_w2aab3b7c80b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Nine thousand eight hundred and fifty-six consecutive patients tested for ANAs were tested by IIF and EliA connective tissue disease screen (Thermo-Fisher). Medical records were reviewed for 2475 patients, including all patients that tested positive\/equivocal by either test and a selection of 500 patients that tested negative.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0905_s_997_w2aab3b7c80b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Concordance between IIF and EliA was 83.1%. AASRD was found in 12.8% of IIF-positive patients, 30.2% of EliA-positive patients and 0.4%, 46.6%, 5.8% and 3.0% of patients that tested, respectively, double negative, double positive, single positive for EliA and single positive for IIF. The association with AASRD increased with increasing antibody level. IIF and EliA were positive in, respectively, 90.4% and 69.9% of systemic lupus erythematosus (n=83), 100% and 84.1% of systemic sclerosis (n=63), 86.7% and 93.3% of Sj\u00f6gren\u2019s syndrome (n=45), 88.2% and 52.9% of polymyositis\/dermatomyositis (n=17), and in all cases of mixed connective tissue disease (n=8). The specificity was projected to be 94%\u201396% for EliA and 86% for IIF. When all AASRDs were taken together, the areas under the curve of receiver operator curves were similar between IIF and EliA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0905_s_996_w2aab3b7c80b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>The positive predictive value for AASRD was higher for EliA than for IIF, but, depending on the disease, EliA might fail to detect antibodies that are detected by IIF. Combining immunoassay with IIF adds value.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2017-0905","type":"journal-article","created":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T22:16:21Z","timestamp":1515363381000},"page":"909-918","source":"Crossref","is-referenced-by-count":38,"title":["Screening for connective tissue disease-associated antibodies by automated immunoassay"],"prefix":"10.1515","volume":"56","author":[{"given":"Philippe","family":"Willems","sequence":"first","affiliation":[{"name":"Laboratory Medicine , University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"De Langhe","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Claessens","sequence":"additional","affiliation":[{"name":"Laboratory Medicine , University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[{"name":"Rheumatology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna","family":"Van Hoeyveld","sequence":"additional","affiliation":[{"name":"Laboratory Medicine , University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Poesen","sequence":"additional","affiliation":[{"name":"Laboratory Medicine , University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vanderschueren","sequence":"additional","affiliation":[{"name":"General Internal Medicine, University Hospitals Leuven , Leuven , Belgium"},{"name":"Department of Microbiology and Immunology , KU Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Blockmans","sequence":"additional","affiliation":[{"name":"General Internal Medicine, University Hospitals Leuven , Leuven , Belgium"},{"name":"Department of Microbiology and Immunology , KU Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology , KU Leuven , Leuven , Belgium"},{"name":"Laboratory Medicine , University Hospitals Gasthuisberg , Herestraat 49 , 3000 Leuven , Belgium , Phone: +32 16 347009, Fax: +32 16 34 79 31"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"key":"2021021304033236627_j_cclm-2017-0905_ref_001_w2aab3b7c80b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17\u201323.","DOI":"10.1136\/annrheumdis-2013-203863"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_002_w2aab3b7c80b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014;2014:315179.","DOI":"10.1155\/2014\/315179"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_003_w2aab3b7c80b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69:1420\u20132.","DOI":"10.1136\/ard.2009.127100"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_004_w2aab3b7c80b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Op de Beeck K, Vermeersch P, Verschueren P, Westhovens R, Mari\u00ebn G, Blockmans D, et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 2011;10:801\u20138.","DOI":"10.1016\/j.autrev.2011.06.005"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_005_w2aab3b7c80b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Op de Beeck K, Vermeersch P, Verschueren P, Westhovens R, Mari\u00ebn G, Blockmans D, et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev 2012;12:137\u201343.","DOI":"10.1016\/j.autrev.2012.02.013"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_006_w2aab3b7c80b1b6b1ab2b2b6Aa","unstructured":"Robier C, Amouzadeh-Ghadikolai O, Stettin M, Reicht G. Comparison of the clinical utility of the Elia CTD Screen to indirect immunofluorescence on Hep-2 cells. Clin Chem Lab Med 2016;54:1365\u201370."},{"key":"2021021304033236627_j_cclm-2017-0905_ref_007_w2aab3b7c80b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977;56:255\u201386.","DOI":"10.1097\/00005792-197707000-00001"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_008_w2aab3b7c80b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.","DOI":"10.1002\/art.1780400928"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_009_w2aab3b7c80b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sj\u00f6gren\u2019s syndrome: a data-driven, expert consensus approach in the Sj\u00f6gren\u2019s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475\u201387.","DOI":"10.1002\/acr.21591"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_010_w2aab3b7c80b1b6b1ab2b2c10Aa","unstructured":"Alarc\u00f3n-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989;16:328\u201334."},{"key":"2021021304033236627_j_cclm-2017-0905_ref_011_w2aab3b7c80b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737\u201347.","DOI":"10.1002\/art.38098"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_012_w2aab3b7c80b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Bossuyt X, Frans J, Hendrickx A, Godefridis G, Westhovens R, Mari\u00ebn G. Detection of anti-SSA antibodies by indirect immunofluorescence. Clin Chem 2004;50:2361\u20139.","DOI":"10.1373\/clinchem.2004.035964"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_013_w2aab3b7c80b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Deng X, Peters B, Ettore MW, Ashworth J, Brunelle LA, Crowson CS, et al. Utility of antinuclear antibody screening by various methods in a clinical laboratory patient cohort. J Appl Lab Med (JALM) 2016;1:36\u201346.","DOI":"10.1373\/jalm.2016.020172"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_014_w2aab3b7c80b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Parker JC, Bunn CC. Sensitivity of the Phadia EliA connective tissue disease screen for less common disease-specific autoantibodies. J Clin Pathol 2011;64:631\u20133.","DOI":"10.1136\/jcp.2010.084756"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_015_w2aab3b7c80b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Bossuyt X, Fieuws S. Detection of antinuclear antibodies: added value of solid phase assay? Ann Rheum Dis 2014;73:e10.","DOI":"10.1136\/annrheumdis-2013-204793"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_016_w2aab3b7c80b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Hoffman IE, Peene I, Veys EM, De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002;48:2171\u20136.","DOI":"10.1093\/clinchem\/48.12.2171"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_017_w2aab3b7c80b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Bossuyt X, Luyckx A. Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples. Clin Chem 2005;51:2426\u20137.","DOI":"10.1373\/clinchem.2005.058552"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_018_w2aab3b7c80b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Avery TY, van de Cruys M, Austen J, Stals F, Damoiseaux JG. Anti-nuclear antibodies in daily clinical practice: prevalence in primary, secondary, and tertiary care. J Immunol Res 2014;2014:401739.","DOI":"10.1155\/2014\/401739"},{"key":"2021021304033236627_j_cclm-2017-0905_ref_019_w2aab3b7c80b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Ghillani P, Andr\u00e9 C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 2011;10: 509\u201313.","DOI":"10.1016\/j.autrev.2011.03.004"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2018.56.issue-6\/cclm-2017-0905\/cclm-2017-0905.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0905\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0905\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:59:54Z","timestamp":1619049594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0905\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,1,8]]},"published-print":{"date-parts":[[2018,5,24]]}},"alternative-id":["10.1515\/cclm-2017-0905"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2017-0905","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1,8]]}}}